|
1
|
Guggenheim DE and Shah MA: Gastric cancer
epidemiology and risk factors. J Surg Oncol. 107:230–236. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality and prevalence across five
continents, Defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Höckel M and Vaupel P: Tumor hypoxia:
Definitions and current clinical biologic and molecular aspects. J
Natl Cancer Inst. 93:266–276. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kitajima Y and Miyazaki K: The Critical
Impact of HIF-1α on Gastric Cancer Biology. Cancers (Basel).
5:15–26. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Semenza GL: Hypoxia-inducible factors: M
ediators of cancer progression and targets for cancer therapy.
Trends Pharmacol Sci. 33:207–214. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Semenza GL: Hypoxia-inducible factor 1:R
egulator of mitochondrial metabolism and mediator of ischemic
preconditioning. Biochim Biophys Acta. 1813:1263–2168. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Keith B, Johnson RS and Simon MC: HIF1α
and HIF2α: Sibling rivalry in hypoxic tumour growth and
progression. Nat Rev Cancer. 12:9–22. 2011.PubMed/NCBI
|
|
8
|
Rey S and Semenza GL: Hypoxia-inducible
factor-1-dependent mechanisms of vascularization and vascular
remodelling. Cardiovasc Res. 86:236–242. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Koh MY, Lemos R Jr, Liu X and Powis G: The
hypoxia-associated factor switches cells from HIF-1α- to
HIF-2α-dependent signaling promoting stem cell characteristics,
aggressive tumor growth and invasion. Cancer Res. 71:4015–4027.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nakamura J, Kitajima Y, Kai K, Hashiguchi
K, Hiraki M, Noshiro H and Miyazaki K: HIF-1alpha is an unfavorable
determinant of relapse in gastric cancer patients who underwent
curative surgery followed by adjuvant 5-FU chemotherapy. Int J
Cancer. 127:1158–1171. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Miyake S, Kitajima Y, Nakamura J, Kai K,
Yanagihara K, Tanaka T, Hiraki M, Miyazaki K and Noshiro H: HIF-1α
is a crucial factor in the development of peritoneal dissemination
via natural metastatic routes in scirrhous gastric cancer. Int J
Oncol. 43:1431–1440. 2013.PubMed/NCBI
|
|
12
|
Yoshimura H, Dhar DK, Kohno H, Kubota H,
Fujii T, Ueda S, Kinugasa S, Tachibana M and Nagasue N: Prognostic
impact of hypoxia-inducible factors 1alpha and 2alpha in colorectal
cancer patients, Correlation with tumor angiogenesis and
cyclooxygenase-2 expression. Clin Cancer Res. 10:8554–8560. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim I, Kim HG, Kim H, Kim HH, Park SK, Uhm
CS, Lee ZH and Koh GY: Hepatic expression, synthesis and secretion
of a novel fibrinogen/angiopoietin-related protein that prevents
endothelial-cell apoptosis. Biochem J. 346:603–610. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mandard S, Zandbergen F, Tan NS, Escher P,
Patsouris D, Koenig W, Kleemann R, Bakker A, Veenman F, Wahli W, et
al: The direct peroxisome proliferator-activated receptor target
fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in
blood plasma as a truncated protein that is increased by
fenofibrate treatment. J Biol Chem. 279:34411–34420. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yoon JC, Chickering TW, Rosen ED, Dussault
B, Qin Y, Soukas A, Friedman JM, Holmes WE and Spiegelman BM:
Peroxisome proliferator-activated receptor gamma target gene
encoding a novel angiopoietin-related protein associated with
adipose differentiation. Mol Cell Biol. 20:5343–5349. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yoshida K, Shimizugawa T, Ono M and
Furukawa H: Angiopoietin-like protein 4 is a potent
hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein
lipase. J Lipid Res. 43:1770–1772. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tan MJ, Teo Z, Sng MK, Zhu P and Tan NS:
Emerging roles of angiopoietin-like 4 in human cancer. Mol Cancer
Res. 10:677–688. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lei X, Shi F, Basu D, Huq A, Routhier S,
Day R and Jin W: Proteolytic processing of angiopoietin-like
protein 4 by proprotein convertases modulates its inhibitory
effects on lipoprotein lipase activity. J Biol Chem.
286:15747–15756. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ge H, Yang G, Huang L, Motola DL,
Pourbahrami T and Li C: Oligomerization and regulated proteolytic
processing of angiopoietin-like protein 4. J Biol Chem.
279:2038–2045. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Oike Y, Akao M, Kubota Y and Suda T:
Angiopoietin-like proteins, Potential new targets for metabolic
syndrome therapy. Trends Mol Med. 11:473–479. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Katoh Y and Katoh M: Comparative
integromics on Angiopoietin family members. Int J Mol Med.
17:1145–1149. 2006.PubMed/NCBI
|
|
22
|
Hato T, Tabata M and Oike Y: The role of
angiopoietin-like proteins in angiogenesis and metabolism. Trends
Cardiovasc Med. 18:6–14. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhu P, Goh YY, Chin HF, Kersten S and Tan
NS: Angiopoietin-like 4: A decade of research. Biosci Rep.
32:211–219. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li H, Ge C, Zhao F, Yan M, Hu C, Jia D,
Tian H, Zhu M, Chen T, Jiang G, et al: Hypoxia-inducible factor 1
alpha-activated angiopoietin-like protein 4 contributes to tumor
metastasis via vascular cell adhesion molecule-1/integrin β1
signaling in human hepatocellular carcinoma. Hepatology.
54:910–919. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nakayama T, Hirakawa H, Shibata K, Nazneen
A, Abe K, Nagayasu T and Taguchi T: Expression of angiopoietin-like
4 (ANGPTL4) in human colorectal cancer, ANGPTL4 promotes venous
invasion and distant metastasis. Oncol Rep. 25:929–935. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Akishima-Fukasawa Y, Ishikawa Y, Akasaka
Y, Uzuki M, Inomata N, Yokoo T, Ishii R, Shimokawa R, Mukai K,
Kiguchi H, et al: Histopathological predictors of regional lymph
node metastasis at the invasive front in early colorectal cancer.
Histopathology. 59:470–481. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim SH, Park YY, Kim SW, Lee JS, Wang D
and DuBois RN: ANGPTL4 induction by prostaglandin E2 under hypoxic
conditions promotes colorectal cancer progression. Cancer Res.
71:7010–7020. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang H, Wong CC, Wei H, Gilkes DM,
Korangath P, Chaturvedi P, Schito L, Chen J, Krishnamachary B,
Winnard PT Jr, et al: HIF-1-dependent expression of
angiopoietin-like 4 and L1CAM mediates vascular metastasis of
hypoxic breast cancer cells to the lungs. Oncogene. 31:1757–1770.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Padua D, Zhang XH, Wang Q, Nadal C, Gerald
WL, Gomis RR and Massagué J: TGFbeta primes breast tumors for lung
metastasis seeding through angiopoietin-like 4. Cell. 133:66–77.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ifon ET, Pang AL, Johnson W, Cashman K,
Zimmerman S, Muralidhar S, Chan WY, Casey J and Rosenthal LJ: U94
alters FN1 and ANGPTL4 gene expression and inhibits tumorigenesis
of prostate cancer cell line PC3. Cancer Cell Int. 5:192005.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Le Jan S, Amy C, Cazes A, Lamandé N,
Favier J, Philippe J, Sibony M, Gasc JM, Corvol P and Germain S:
Angiopoietin-like 4 is a proangiogenic factor produced during
ischemia and in conventional renal cell carcinoma. Am J Pathol.
162:1521–1528. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Verine J, Lehmann-Che J, Soliman H,
Feugeas JP, Vidal JS, Mongiat-Artus P, Belhadj S, Philippe J,
Lesage M, Wittmer E, et al: Determination of angptl4 mRNA as a
diagnostic marker of primary and metastatic clear cell renal-cell
carcinoma. PLoS One. 5:e104212010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hu J, Jham BC, Ma T, Friedman ER, Ferreira
L, Wright JM, Accurso B, Allen CM, Basile JR and Montaner S:
Angiopoietin-like 4: A novel molecular hallmark in oral Kaposi's
sarcoma. Oral Oncol. 47:371–375. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ma T, Jham BC, Hu J, Friedman ER, Basile
JR, Molinolo A, Sodhi A and Montaner S: Viral G protein-coupled
receptor up-regulates Angiopoietin-like 4 promoting angiogenesis
and vascular permeability in Kaposi's sarcoma. Proc Natl Acad Sci
USA. 107:14363–14368. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nakayama T, Hirakawa H, Shibata K, Abe K,
Nagayasu T and Taguchi T: Expression of angiopoietin-like 4 in
human gastric cancer, ANGPTL4 promotes venous invasion. Oncol Rep.
24:599–606. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Japanese Gastric: CancerA ssociation.
Histopathology. Gastric Cancer. 14:101–112. 2011.PubMed/NCBI
|
|
37
|
Galaup A, Cazes A, Le Jan S, Philippe J,
Connault E, Le Coz E, Mekid H, Mir LM, Opolon P, Corvol P, et al:
Angiopoietin-like 4 prevents metastasis through inhibition of
vascular permeability and tumor cell motility and invasiveness.
Proc Natl Acad Sci USA. 103:18721–18726. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ito Y, Oike Y, Yasunaga K, Hamada K,
Miyata K, Matsumoto S, Sugano S, Tanihara H, Masuho Y and Suda T:
Inhibition of angiogenesis and vascular leakiness by
angiopoietin-related protein 4. Cancer Res. 63:6651–6657.
2003.PubMed/NCBI
|
